1-[[2-(2,4-dichlorophenoxy)-1-oxoethyl]amino]-3-(4-methoxyphenyl)thiourea is a complex chemical compound with the following characteristics:
* **Structure:** The compound is a thiourea derivative, meaning it contains a thiourea group (-NH-CS-NH-). This group is attached to a 4-methoxyphenyl group and a modified phenoxy group.
* **Properties:** The compound likely exhibits specific physical and chemical properties due to its structure, including potential solubility, melting point, and reactivity.
**Importance for research:**
The importance of this compound for research lies in its potential applications, which are likely related to its specific structure and properties. Some possible areas of interest include:
* **Herbicidal activity:** The presence of the 2,4-dichlorophenoxy group suggests a potential link to herbicides. This group is a common motif in herbicides, targeting plant growth regulators. Further investigation could reveal if this compound exhibits herbicidal activity and its mechanism of action.
* **Pharmacological activity:** Thiourea derivatives are known to possess a range of pharmacological activities, such as anti-inflammatory, antioxidant, and antimicrobial effects. This specific compound could be investigated for its potential therapeutic properties.
* **Material science:** The compound might possess unique properties relevant to material science. For instance, its ability to form crystals or its interactions with specific materials could be investigated for potential applications in areas like organic electronics or advanced materials.
**Research implications:**
Research involving 1-[[2-(2,4-dichlorophenoxy)-1-oxoethyl]amino]-3-(4-methoxyphenyl)thiourea could contribute to:
* **Development of new herbicides:** Understanding its herbicidal activity could lead to the development of more efficient and environmentally friendly herbicides.
* **Discovery of new drugs:** Investigating its pharmacological properties could reveal potential therapeutic uses for treating various diseases.
* **Creation of innovative materials:** Its unique properties could contribute to the development of advanced materials with specific applications in different fields.
**Note:** It's important to emphasize that this information is based on the compound's structure and potential applications derived from similar compounds. Further research is necessary to determine the specific properties and applications of this particular compound.
ID Source | ID |
---|---|
PubMed CID | 4128012 |
CHEMBL ID | 1428238 |
CHEBI ID | 109394 |
Synonym |
---|
smr000236375 |
MLS000722976 |
CHEBI:109394 |
AKOS005109756 |
1-[[2-(2,4-dichlorophenoxy)acetyl]amino]-3-(4-methoxyphenyl)thiourea |
AKOS003624701 |
HMS2558P11 |
STL282423 |
2-[(2,4-dichlorophenoxy)acetyl]-n-(4-methoxyphenyl)hydrazinecarbothioamide |
1-(2-(2,4-dichlorophenoxy)acetyl)-4-(4-methoxyphenyl)thiosemicarbazide |
69026-42-2 |
F0807-0307 |
(e)-2-(2-(2,4-dichlorophenoxy)acetyl)-n-(4-methoxyphenyl)hydrazinecarbimidothioic acid |
2-(2,4-dichlorophenoxy)-n-{[(4-methoxyphenyl)carbamothioyl]amino}acetamide |
MS-7596 |
CHEMBL1428238 |
1-[[2-(2,4-dichlorophenoxy)-1-oxoethyl]amino]-3-(4-methoxyphenyl)thiourea |
Q27188513 |
mfcd00955347 |
2-(2-(2,4-dichlorophenoxy)acetyl)-n-(4-methoxyphenyl)hydrazinecarbothioamide |
2-(2,4-dichlorophenoxy)-n-{[(e)-(4-methoxyphenyl)thio(carbonoimidyl)]amino}acetamide |
Class | Description |
---|---|
substituted aniline | |
methoxybenzenes | Any aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 17.7407 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 70.7946 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
TDP1 protein | Homo sapiens (human) | Potency | 20.5962 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 19.9526 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 4.4668 | 0.0018 | 15.6638 | 39.8107 | AID894 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 2.2387 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 17.7828 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
geminin | Homo sapiens (human) | Potency | 0.0046 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 8.9125 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 1.4125 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |